Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

Maitreyee Hazarika, Meredith K. Chuk, Marc R. Theoret et al. · Clinical Cancer Research · 2017 · 182 citations

Medicine, Pharmacology, Pharmacotherapy +17

BILATERAL DRUG (IPILIMUMAB)-INDUCED VITRITIS, CHOROIDITIS, AND SEROUS RETINAL DETACHMENTS SUGGESTIVE OF VOGT–KOYANAGI–HARADA SYNDROME

Ryan Wong, Jimmy K. Lee, John J. Huang · Retinal Cases & Brief Reports · 2012 · 80 citations

Medicine, Immunology, Ophthalmology +16

Cyclosporine for Dry Eye Associated With Nivolumab

Alexander T. Nguyen, Maxwell Elia, Miguel A. Materin et al. · Cornea · 2016 · 63 citations

Medicine, Oncology, Ophthalmology +17

Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort

Cyril Maire, S. Vercambre‐Darras, Patrick Devos et al. · Journal of the European Academy of Dermatology and Venereology · 2011 · 37 citations

Life Sciences, Dermatology, Oncology +17